US Stocks
Radius Health Inc.
Radius Health Inc.

Radius Health Inc. (RDUS)


  • $







Key Stats

Today Low/High$21.2 / $22.2
52 Week Low/High$11.95 / $26.16
P/E ratio-16.54
Market Cap$1.01B

Company Details

Radius Health Inc. is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine and other therapeutics. Radius' lead product, TYMLOS® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide transdermal system for potential use in the treatment of postmenopausal women with osteoporosis; the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group; and the investigational drug RAD011, a synthetic cannabidiol oral solution with potential utilization in multiple endocrine and metabolic orphan diseases, initially targeting Prader-Willi syndrome.
OrganisationRadius Health Inc.
HeadquatersWaltham, Massachusetts, US
IndustryHealth Technology
CEOG. Kelly Martin

Discover more

Frequently Asked Questions

What is Radius Health Inc. (RDUS) share price today?

Can Indians buy Radius Health Inc. (RDUS) shares?

How can I buy Radius Health Inc. (RDUS) shares from India?

Can Fractional shares of Radius Health Inc. (RDUS) be purchased?

What are the documents required to start investing in Radius Health Inc. (RDUS) stocks?

We are a SEBI registered investement advisor